Public Funding for Oxygenica Ltd

This project aims to develop an innovative cancer treatment that focuses on **improving the function and longevity of immune cells**, specifically T cells, within the challenging environment of **solid tumours**. T cells play a crucial role in our body's ability to combat cancer; however, they often become exhausted and lose their effectiveness when facing the harsh conditions present within solid tumours. Our proposed solution involves the development of a **cutting-edge genetic tool** that can be introduced into **T cells**, allowing them to better withstand the difficult environment and maintain their ability to fight cancer. This tool will be designed to activate only under specific conditions, ensuring that it does not negatively impact the natural function of the T cells. By developing this groundbreaking approach, we aim to enhance the **effectiveness of existing cancer immunotherapies**, providing a superior treatment option for patients with solid tumours. This innovation holds significant promise for improving patient outcomes and transforming cancer treatment in the years to come. The **market opportunity** for this novel cancer treatment is vast, as it addresses an unmet need in the field of **immuno-oncology**. The successful development and implementation of this solution will not only benefit patients but also support the growth of new businesses within the UK and European ecosystems. Additionally, the **socio-economic impact** of this innovative cancer therapy will be substantial, as it has the potential to reduce healthcare costs and improve the quality of life for countless individuals affected by solid tumours. In summary, this project represents a significant advancement in the fight against cancer and holds the potential to transform the treatment landscape for the better.